GENOR BIOPHARMA DL-00002 Total Liabilities
GENOR BIOPHARMA DL-00002 total liabilities. Based on the latest financial reports, GENOR BIOPHARMA DL-00002 (67N0) has total liabilities worth €226.09 Million EUR (≈ $264.32 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See GENOR BIOPHARMA DL-00002 current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of GENOR BIOPHARMA DL-00002 (2021–2024)
Total liabilities of GENOR BIOPHARMA DL-00002 from 2021 to 2024. This chart illustrates how GENOR BIOPHARMA DL-00002's total liabilities have evolved over time, based on quarterly financial data.
GENOR BIOPHARMA DL-00002 Competitors by Total Liabilities
The table below lists competitors of GENOR BIOPHARMA DL-00002 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Seritage Growth Properties
NYSE:SRG
|
USA | $59.85 Million |
|
Korea Fuel-Tech Corporation
KQ:123410
|
Korea | ₩286.07 Billion |
|
Loop Telecommunication International Inc
TW:3025
|
Taiwan | NT$399.52 Million |
|
Merck Tbk
JK:MERK
|
Indonesia | Rp154.71 Billion |
|
Leadtrend Technology Corp
TW:3588
|
Taiwan | NT$244.85 Million |
|
Gelecek Varlik Yonetimi AS
IS:GLCVY
|
Turkey | TL530.35 Million |
|
Yew Lee Pacific Group Berhad
KLSE:0248
|
Malaysia | RM3.26 Million |
|
Englewood Lab Inc
KQ:950140
|
Korea | ₩75.21 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down GENOR BIOPHARMA DL-00002's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of GENOR BIOPHARMA DL-00002.
Liquidity & Leverage Metrics
GENOR BIOPHARMA DL-00002 Total Liabilities Ratios Explained
GENOR BIOPHARMA DL-00002 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENOR BIOPHARMA DL-00002's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENOR BIOPHARMA DL-00002 (2021–2024)
The table below shows the annual total liabilities of GENOR BIOPHARMA DL-00002 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €138.05 Million ≈ $161.39 Million |
-46.11% |
| 2023-12-31 | €256.18 Million ≈ $299.50 Million |
-17.33% |
| 2022-12-31 | €309.87 Million ≈ $362.27 Million |
-16.19% |
| 2021-12-31 | €369.73 Million ≈ $432.25 Million |
-- |
About GENOR BIOPHARMA DL-00002
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical tri… Read more